Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 5 pembrolizumab 4 Biopsy 4 durvalumab 3 atezolizumab 3 Radiotherapy 3 Radiosurgery 3 Cyclophosphamide 3 Bevacizumab 3 palbociclib 2 niraparib 2 abemaciclib 2 Trastuzumab 2 Temozolomide 2 Taxes 2 Surgical Procedures, Operative 2 Specimen Handling 2 Melphalan 2 Letrozole 2 Ketamine 2 Irinotecan 2 Hydrocortisone 2 Gemcitabine 2 Fluorodeoxyglucose F18 2 Ferrosoferric Oxide 2 Dexamethasone 2 Curcumin 2 Blood Specimen Collection 2 Albumin-Bound Paclitaxel 2 130-nm albumin-bound paclitaxel 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Withdrawn × glembatumumab vedotin × Clear all

NCT03473691 2024-12-09

Breast50

University of Virginia

Phase EARLY_PHASE1 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡